Gout symptoms arrive abruptly, often in the early hours, and the joint involved can feel hot enough to burn. The medical explanation is precise: monosodium urate crystals, formed when uric acid concentrations exceed their solubility point, settle in a joint and trigger an intense inflammatory response. What follows is not a slow ache but an acute flare that reaches full force within 12 to 24 hours.
Uric acid itself is a normal breakdown product of purines, compounds found in many foods and made by the body. Most people clear it through the kidneys. Gout develops when that clearance is not efficient enough, or when production is too high, leaving serum urate persistently above the saturation point of roughly 6.8 mg/dL (404 micromoles per litre). Hyperuricaemia is common; gout is not. Many people with high uric acid never have a flare, which means the clinical question is about crystals and inflammation, not just a blood number.
What the Evidence Says About Symptoms, Diagnosis, and Long-Term Urate Control
The condition operates in two phases. The acute flare is the emergency; the underlying disorder is chronic urate deposition. Confusing the two leads to undertreatment, because a flare can resolve while the crystals remain.
How a Gout Flare Actually Presents
The first metatarsophalangeal joint at the base of the big toe is the classic site, a pattern known as podagra. But the midfoot, ankle, knee, wrist, finger, and elbow can all be involved. Inflammation is the hallmark: redness, swelling, warmth, and pain out of proportion to the visible change. The pain is often described as intolerable to even the weight of a bedsheet. Fever can accompany a severe flare, and the episode may be mistaken for infection, particularly when the knee or ankle is involved.
Early attacks tend to affect one joint and resolve over days to a week or two, sometimes with complete recovery. Later, untreated disease can become polyarticular and chronic. Tophi, firm deposits of urate crystals under the skin, appear around joints, ears, and tendons after years of high urate burden. They are a sign of severe, long-standing disease rather than an early symptom.
Diagnosis: Crystals, Not Just Urate Levels
Hyperuricaemia supports the diagnosis but does not confirm it. During an acute flare, serum urate can fall into the normal range because of urinary excretion shifts and cytokine effects. The reference standard is synovial fluid aspiration: a needle draws fluid from the inflamed joint, and polarised light microscopy identifies needle-shaped, negatively birefringent monosodium urate crystals. If crystals are seen, the diagnosis is secured.
Imaging contributes when joint aspiration is not possible. Ultrasound can show the double contour sign, a hyperechoic layer over the joint cartilage. Dual-energy computed tomography can distinguish urate deposits from calcium. These tools help in atypical cases, but they do not replace the clinical picture and crystal identification.
Treating the Acute Flare
Time matters more than the choice among several effective drugs. The 2020 American College of Rheumatology guideline strongly recommends colchicine, nonsteroidal anti-inflammatory drugs, glucocorticoids, and, in selected refractory cases, interleukin-1 inhibitors as treatment options. The choice depends on kidney function, stomach history, cardiovascular risk, and the patient's other medicines. There is no one-size-fits-all flare drug.
| Treatment | Evidence-based role | Main cautions |
|---|---|---|
| NSAIDs | First-line for acute flares; fast relief when started early | Kidney injury, gastrointestinal bleeding, cardiovascular risk, and fluid retention |
| Colchicine | First-line, low-dose regimen within 36 hours | Diarrhoea, nausea, muscle toxicity at high doses, and drug interactions with strong CYP3A4 inhibitors |
| Glucocorticoids | First-line oral, injected, or intra-articular option | Hyperglycaemia, infection risk, fluid retention, and bone loss with prolonged use |
| Interleukin-1 inhibitors | Refractory flares, usually specialist-led | Infection risk, injection-site reactions, high cost, and limited long-term data |
Low-dose colchicine is preferred over higher doses because the old high-dose regimens caused severe diarrhoea without adding benefit. In the United States labelling, the low-dose regimen begins with 1.2 mg at the first sign of a flare, followed by 0.6 mg an hour later. Glucocorticoids can be given orally, as an intramuscular injection, or directly into the joint. NSAIDs require caution in people with kidney disease, peptic ulcer disease, or cardiovascular disease. For flares that fail these options, the biologic agents anakinra and canakinumab block the interleukin-1 pathway and are used mainly by specialists.
The American College of Rheumatology gout guideline highlights that treating the flare is only the first half of the problem. Preventing the next one requires a different strategy aimed at urate.
Urate-Lowering Therapy: The Long-Term Fix
Once the decision is made to lower urate over the long term, the target is more important than the specific drug chosen. Urate-lowering therapy is recommended for people with two or more flares a year, tophi, chronic kidney disease, or urate kidney stones. The goal is not merely to lower the blood value but to bring serum urate below 6.0 mg/dL, and below 5.0 mg/dL for those with tophaceous disease, long enough for crystals to dissolve. Treat-to-target monitoring works: a urate level below 6 mg/dL is associated with fewer flares over time. The process can take months to years, not days.
Allopurinol remains the usual first-line urate-lowering drug. It inhibits xanthine oxidase, the enzyme that produces uric acid. Guidelines recommend starting low, typically 100 mg daily or less in kidney impairment, and increasing gradually to target. Starting at a high dose paradoxically increases early flare risk. Before prescribing allopurinol, clinicians in high-risk populations should consider testing for the HLA-B*5801 allele; the marker is most relevant in people of Han Chinese, Korean, Thai, and African American descent, where the risk of severe hypersensitivity reactions is higher.
Febuxostat also inhibits xanthine oxidase, but its cardiovascular safety record changed practice. The CARES trial, required by regulators, found higher all-cause mortality and cardiovascular mortality among gout patients with established cardiovascular disease treated with febuxostat compared with allopurinol. The US Food and Drug Administration responded with a boxed warning and advised limiting febuxostat to patients who cannot take allopurinol or who have not reached target on allopurinol.
Uricosuric drugs such as probenecid increase urate excretion and suit some patients with normal kidney function. Pegloticase, an intravenous uricase enzyme, is reserved for refractory gout that has not responded to oral options. It lowers urate rapidly and can shrink tophi, but it causes infusion reactions and loses effectiveness when antibodies develop. More recent trial data show that adding methotrexate can improve the durability of pegloticase response, an important practical detail for advanced disease.
Diet and Weight: Helpful, but Seldom Curative Alone
Diet matters, but the effect size is smaller than many patients expect. Beer and liquor, sugar-sweetened beverages, red meat, organ meats, and some seafoods raise urate or increase flare risk. Weight loss and a DASH-style diet lower urate and reduce flares. Low-fat dairy may be protective, and coffee intake has been associated with lower gout risk in observational studies. Cherry products have a modest evidence base at best; they are not a substitute for urate-lowering medication.
During the first months of urate-lowering therapy, a low dose of colchicine or an NSAID is often prescribed as flare prophylaxis. The rationale is simple: as urate levels fall, crystals begin to mobilise from tissue deposits, and this can provoke exactly the inflammatory response the treatment is meant to prevent. Prophylaxis typically continues for at least three to six months after the urate target is reached.
The Question the Press Releases Avoid
Most guidelines agree on the basic arithmetic: lower serum urate below target, keep it there, and flares decline and tophi regress; joint damage slows as the crystal burden falls. The harder question is why so few people with gout receive that treatment for long enough. Adherence to allopurinol is notoriously poor, often because patients stop during an early flare or were never told the drug is lifelong. The scientific problem is no longer identifying what works; it is translating a decades-old, inexpensive treatment into consistent long-term use. For patients, the practical first step is to ask what the serum urate target is and when the next blood test will check it.
Further background on symptoms and diagnosis is available from the National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Photo by Alina Prokudina on Unsplash